Literature DB >> 19944972

The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

William Humphries1, Jun Wei, John H Sampson, Amy B Heimberger.   

Abstract

The role of regulatory T cells (Tregs) in mediating immune suppression of anti-tumor immune responses is increasingly appreciated in patients with malignancies-especially within the malignant glioma patient population. This article discuss the role and prognostic significance of Tregs within glioma patients and delineates potential approaches for their inhibition that can be used alone or in combination with other immune therapeutics in clinical trials and in the clinical settings of recurrent or residual disease.

Entities:  

Mesh：

Year:  2010        PMID： 19944972      PMCID： PMC2786818          DOI： 10.1016/j.nec.2009.08.012

Source DB:  PubMed          Journal:  Neurosurg Clin N Am        ISSN： 1042-3680            Impact factor:   2.509


  120 in total

1.  B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells.

Authors:  Z Yi-qun; K Lorré; M de Boer; J L Ceuppens
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

2.  Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages.

Authors:  Y F Yang; J P Zou; J Mu; R Wijesuriya; S Ono; T Walunas; J Bluestone; H Fujiwara; T Hamaoka
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.

Authors:  G D MacLean; D W Miles; R D Rubens; M A Reddish; B M Longenecker
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1996-07

4.  Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.

Authors:  K Tsung; J B Meko; Y L Tsung; G R Peplinski; J A Norton
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

5.  T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors.

Authors:  L A Morford; L H Elliott; S L Carlson; W H Brooks; T L Roszman
Journal:  J Immunol       Date:  1997-11-01       Impact factor: 5.422

6.  Characterization of a spontaneous murine astrocytoma and abrogation of its tumorigenicity by cytokine secretion.

Authors:  J H Sampson; D M Ashley; G E Archer; H E Fuchs; G Dranoff; L P Hale; D D Bigner
Journal:  Neurosurgery       Date:  1997-12       Impact factor: 4.654

7.  A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.

Authors:  A Engert; V Diehl; R Schnell; A Radszuhn; M T Hatwig; S Drillich; G Schön; H Bohlen; H Tesch; M L Hansmann; S Barth; J Schindler; V Ghetie; J Uhr; E Vitetta
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

8.  Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.

Authors:  R Schnell; E Vitetta; J Schindler; S Barth; U Winkler; P Borchmann; M L Hansmann; V Diehl; V Ghetie; A Engert
Journal:  Leuk Lymphoma       Date:  1998-08

9.  Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells.

Authors:  A Aquino; S P Prete; J W Greiner; A Giuliani; G Graziani; M Turriziani; R De Filippi; G Masci; E Bonmassar; L De Vecchis
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

10.  CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.

Authors:  A M Thornton; E M Shevach
Journal:  J Exp Med       Date:  1998-07-20       Impact factor: 14.307
View more
  29 in total

Review 1.  The Gut-Brain Axis, Paving the Way to Brain Cancer.

Authors:  Ruty Mehrian-Shai; Juergen K V Reichardt; Curtis C Harris; Amos Toren
Journal:  Trends Cancer       Date:  2019-03-16

Review 2.  Is HCMV a tumor promoter?

Authors:  Liliana Soroceanu; Charles S Cobbs
Journal:  Virus Res       Date:  2010-10-29       Impact factor: 3.303

3.  Scutellaria extract and wogonin inhibit tumor-mediated induction of T(reg) cells via inhibition of TGF-β1 activity.

Authors:  Sagar Dandawate; Linford Williams; Nirmal Joshee; Agnes M Rimando; Sandeep Mittal; Archana Thakur; Lawrence G Lum; Prahlad Parajuli
Journal:  Cancer Immunol Immunother       Date:  2011-11-06       Impact factor: 6.968

Review 4.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Authors:  Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

5.  Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

Authors:  John F de Groot; Kathleen R Lamborn; Susan M Chang; Mark R Gilbert; Timothy F Cloughesy; Kenneth Aldape; Jun Yao; Edward F Jackson; Frank Lieberman; H Ian Robins; Minesh P Mehta; Andrew B Lassman; Lisa M Deangelis; W K Alfred Yung; Alice Chen; Michael D Prados; Patrick Y Wen
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 6.  Vaccine therapies in malignant glioma.

Authors:  Taemin Oh; Eli T Sayegh; Shayan Fakurnejad; Daniel Oyon; Jonathan Balquiedra Lamano; Joseph David DiDomenico; Orin Bloch; Andrew T Parsa
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 7.  Immunotherapy of Primary Brain Tumors: Facts and Hopes.

Authors:  Robin A Buerki; Zinal S Chheda; Hideho Okada
Journal:  Clin Cancer Res       Date:  2018-06-05       Impact factor: 12.531

8.  Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model.

Authors:  Michael Chae; Timothy E Peterson; Alexis Balgeman; Selby Chen; Lei Zhang; Danielle N Renner; Aaron J Johnson; Ian F Parney
Journal:  Neuro Oncol       Date:  2014-12-23       Impact factor: 12.300

Review 9.  Targeting glioma stem cells: a novel framework for brain tumors.

Authors:  Emanuela Binello; Isabelle M Germano
Journal:  Cancer Sci       Date:  2011-09-16       Impact factor: 6.716

10.  Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.

Authors:  Neha Kamran; Padma Kadiyala; Meghna Saxena; Marianela Candolfi; Youping Li; Mariela A Moreno-Ayala; Nicholas Raja; Diana Shah; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2017-01-04       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.